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Summary. Background:Prothrombin (FII)G20210Amutation
and elevated plasma prothrombin activity are known risk
factors for venous thrombosis. The risk of venous thrombosis
among 19911G carriers of the prothrombin A19911G poly-
morphismhas not been extensively investigated. Objectives and
methods:We assessed prothrombin activity, FIIG20210A, and
FIIA19911G polymorphisms in a large population-based case–
control study, the Multiple Environmental and Genetic
Assessment (MEGA) study of risk factors for venous throm-
bosis. Four thousand three hundred and sixty-five consecutive
patientswith a first episode of deep vein thrombosis of the leg or
pulmonary embolism were included. The control group (n ¼
4779) consisted of partners of patients or persons gatheredusing
a random-digit dialing method. We studied the effect of
FIIA19911G polymorphism on prothrombin activity
and thrombosis risk, also in combination with factor V
Leiden. Results: Among FII20210-GG control subjects,
FII19911-GG carriers had 7.1% [95% confidence interval
(CI): 5.7–8.5] highermean prothrombin activity thanFII19911-
AAcarriers and the risk forGGcarrierswas 1.43-fold increased
compared to AA carriers [odds ratio (OR) 1.43; 95%CI: 1.27–
1.61]. Among FII20210-GA control carriers, the mean pro-
thrombin activity in both FII19911-AA and -AG carriers was
nearly equivalent [131.7% and 133.4%; mean difference (95%
CI) ¼ 1.7% ()7.2–10.7)]. Because of genetic linkage, FII19911-
GG carriers were very rare on a FII20210-GA background, as
only one FII20210A carrier had FII19911-GG. In FII20210-
GAcarriers, theOR increased from3.05 (95%CI: 2.17–4.27) in
subjects with FII19911-AA to 3.33 (2.28–4.85) in subjects with
FII19911-AG, compared to those with FII20210-GG and
FII19911-AA. Conclusions: The FIIA19911G polymorphism
is associated with mildly elevated prothrombin activity and is a
risk factor for venous thrombosis.
Keywords: prothrombin mutations, risk factor, venous throm-
bosis.
Introduction
Venous thrombosis is a multicausal disease involving both
genetic and acquired risk factors [1]. Various risk factors, such
as factor (F)V Leiden [2] and prothrombin 20210A mutation
[3], high concentrations of FVIII [4], and hyperhomocystein-
aemia [5], may occur together in an individual [6–8]. The
prothrombin 20210A allele is associated with increased plasma
prothrombin activity and a 3- to 7-fold increased risk of venous
thrombosis [3,9,10]. There is some evidence [11] showing that
another polymorphism, prothrombin (FII) A19911G, is also
associated with slightly higher plasma prothrombin activity. So
far, only two studies [11,12] have investigated the risk of venous
thrombosis in the presence of the prothrombin A19911G
polymorphism. Overall, this polymorphism could not be
shown to play a clear role in the development of deep vein
thrombosis (DVT); the prothrombin A19911G polymorphism
did not affect the thrombotic risk in 20210-GG subjects in the
Leiden Thrombophilia Study (LETS) [11] and equivocal results
in another study [12]. The FII19911-AG genotype seemed to
increase the risk of venous thrombosis in carriers of the
FII20210-GA genotype in both studies. However, the confid-
ence intervals were wide as a result of the low number of
individuals carrying the FII20210-GA genotype [11,12].
Because of the linkage disequilibrium between FII20210A
allele and FII19911A allele, chromosomes carrying the
FII20210A mutation nearly always have the FII19911A allele
as well [11,13,14]. Therefore, FII19911-GG on a FII20210-GA
background is very rare. A study using various plasmid
constructs transfected in tissue culture cells demonstrated that
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the intronic prothrombin A19911G polymorphism was itself
functional [15]. It is a functional change that identifies the
intronic motif CAGGG as an important enhancer of pro-
thrombin pre-mRNA splicing (van der Putten et al., submit-
ted).We have performed a large population-based case–control
study including 4365 patients with venous thrombosis and 4779
control subjects. The aim of this study was to clarify the role of
the prothrombin A19911G polymorphism and the association
with prothrombin activity in venous thrombosis. Also, the role
of the prothrombin A19911G polymorphism together with
FII20210A and FV Leiden mutation on the risk of venous
thrombosis was assessed.
Materials and methods
Subjects and data collection
Patients and control subjects are derived from the Multiple
Environmental and Genetic Assessment (MEGA) study of risk
factors for venous thrombosis, which is a large population-
based case–control study. We recruited 6578 consecutively
diagnosed patients from six regional anticoagulation clinics in
theNetherlands betweenMarch 1999 and September 2004with
a first episode of DVT of the leg or pulmonary embolism (PE).
We excluded those with severe psychiatric disease (n ¼ 117)
and those not understanding Dutch (n ¼ 126). Among the
eligible patients, 276 died before they could participate, 82
patients had a terminal disease and 922 patients could not be
located or refused to participate in full. A total of 5055 patients
participated in the study.
Partners of patients were invited to participate as a control
subject. Additional control subjects were recruited by using a
random-digit dialing (RDD) method [16] and were drawn
from the population in the same area as the patients
addresses. For both control groups, the same exclusion
criteria as for the cases were applied. This resulted in 6220
population control subjects: 3220 partner controls and 3000
RDD controls. After providing written informed consent, all
participants were asked to complete a questionnaire on
acquired risk factors of venous thrombosis, as well as
comorbid circumstances such as cancer and liver disease.
The body mass index (BMI) was calculated from self-reported
weight and height. We used the date of diagnosis of
thrombosis as reported by the participants as the index date
for patients. For partner controls, the index date was the same
as the index date of their partners (the patients). For RDD
controls, the index date was the date they gave in the
questionnaire. When the participant was unable to fill in the
questionnaire, we asked questions by telephone using a
standard mini-questionnaire (6.5%).
The diagnosis of clinically suspected DVT of the leg was
based on compression ultrasonography. Objective testing of
clinically suspected PE was based on perfusion and ventilation
scintigraphy, pulmonary angiography or helical computed
tomography. The validation of thrombosis diagnosis in a ran-
dom sample of patients has been described previously [17].
Collection of blood and buccal swabs, and laboratory analysis
Three months after discontinuation of the oral anticoagulation
therapy, patients and partner controls were invited for an
interview. Patients with an indication for life-long anticoagu-
lant therapy were interviewed approximately 1 year after the
index date, together with their partners. RDD controls were
also invited for an interview. A blood sample was taken on the
date of the interview. Participants who were unable to provide
a blood sample were sent a buccal swab. From November
2003, blood draws in patients and partner control subjects were
replaced by buccal swabs completely.
Venous blood was obtained after the participant had fasted
overnight. Blood was collected into vacuum tubes containing
0.1 volume 106 mmol L)1 trisodium citrate, and centrifuged
for 10 min at 2000 · g at room temperature. Plasma was
stored at )70C. Genomic DNA was isolated from leukocytes
using standard methods [17] and stored at 4C. Buccal swabs
were used for DNA extraction using a previously described
method [17] and stored at 4C.
Prothrombin activity (FII:C) was measured with a mechan-
ical clot detection method using STA Neoplastin Plus as an
activator on a STA-R coagulation analyzer following the
instructions of the manufacturer (Diagnostica Stago, Asnieres,
France). Calibration with Preciclot I (normal FII:C) and
Preciclot II (low FII:C) was performed every hour during a
series of measurements including at the beginning and at the
end of a series. For Preciclot I, the intra-assay coefficient of
variation (CV) was 3.7% and the inter-assay CV 4.0%. For
Preciclot II, the intra-assay CV was 2.5% and inter-assay CV
2.7%.
Screening for FV Leiden and FII G20210A was carried out
on genomic DNA as described previously [2,3]. FII A19911G
was tested using the previously described method [11] or
TaqMan assay (fluorogenic 5¢ nuclease assay) [18].
Statistical analyses
DNAwas available for 4382 patients and 4803 control subjects.
DNA samples that did not give conclusive results on FV
Leiden, FII G20210A or FII A19911G (17 samples from
patients and 24 of control subjects) were excluded, resulting in
4365 patients and 4779 control subjects with DNA results.
Plasma was available for 2414 patients and 2893 control
subjects. However, 49 lipemic, hemolyzed or inadequately
drawn blood samples equally distributed among patients and
control subjects were discarded. In five plasma samples,
prothrombin activity could not be measured and three persons
had extreme values (FII:C 16%, 35% and 455%), which were
outliers distinct from the rest of the data. 25 persons reported a
history of liver disease. Three hundred and thirty-three persons
were using oral anticoagulants at the time of the blood draw or
during the previous 8 weeks, and for 42 persons it was
unknown if or when they had been using anticoagulants. After
exclusion of these samples, 2034 patients and 2816 control
subjects could be used in the analyses relating to FII:C.
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Odds ratios (ORs) were calculated as estimates of the relative
risk of venous thrombosis in the standard unmatched fashion.
A 95% confidence interval (95% CI) was constructed accord-
ing to Woolf [19]. Adjustment for age, sex and BMI (kg m)2)
was performed by unconditional logistic regression. To assess a
dose–response relation, we stratified the prothrombin values of
control subjects into quartiles (and deciles) and calculated the
ORs for the higher quartiles (and deciles) relative to the lowest
quartile (and decile). The population attributable risks for
FII19911, FV Leiden and FII20210 were estimated according
to Bruzzi et al. [20].
To assess the joint effect of FIIA19911G with either FV
Leiden or FII20210A, we calculated a synergy index (SI) as
previously described [17]. An SI of one or more indicates
multiplicativity of effects and an SI of less than one means a
lower than multiplicative effect. In the latter case, there may
still be an additive interaction. The underlying assumption of
the SI and additive model is independence of exposures. All
computations were performed with the use of SPSS software,
version 12.0.1 (SPSS Inc., Chicago, IL, USA).
Results
Study population
Among 4365 patients and 4779 control subjects, there were
1990 men (45.6%) in the patient group and 2225 men (46.6%)
in the control group. There were two male-to-female transsex-
uals and one Klinefelter syndrome (47XXY) in the patient
group, who were considered as men in the statistical analyses.
The mean age in the patients (48.5; 5th–95th percentile 26.1–
67.7) was similar to that in the control subjects (47.9; 5th–95th
percentile 26.8–66.7). Of all the patients, 2505 (57.4%) had a
DVT in the leg only, 1317 (30.2%) a PE only and 543 (12.4%) a
DVT in the leg combined with a PE.
Prevalence, venous thrombotic risk, and population
attributable risks of the FII19911G allele, the FII20210A allele
and FV Leiden
Table 1 shows the genotype distribution of the FIIA19911G
polymorphism in the patients and control subjects. The
FII19911A allele frequency in the control subjects was 51%.
The distribution of the FII19911 genotypes in the control
subjects did not differ from Hardy–Weinberg equilibrium.
Overall, the FII19911G allele slightly increased the venous
thrombotic risk compared to the FII19911A allele (AG vs. AA
OR 1.09; 95% CI: 0.98–1.20; GG vs. AA OR 1.32; 95% CI:
1.18–1.48). The exclusion of FII20210A carriers slightly
increased these ORs, because FII20210A, being a relatively
strong risk factor, is nearly always present on the same
chromosome as FII19911A (Table 1). The exclusion of FV
Leiden carriers from the overall group did not affect these ORs
(data not shown). The exclusion of both FII20210A and FV
Leiden carriers gave similar ORs as the exclusion of FII20210A
carriers alone. Carriers of the FIIG20210A mutation had a
2.73-fold increased risk of venous thrombosis (OR 2.73; 95%
CI: 2.13–3.50). FV Leiden carriers had a 3.33-fold increased
risk (OR 3.33; 95%CI: 2.86–3.86). The population attributable
risk of FII19911G was 11.0%, of FV Leiden 11.0%, and of
FII20210A 3.2%.
Plasma prothrombin activity (FII:C) associated with the
G20210A genotype and A19911G polymorphism
A total of 2034 patients and 2816 control subjects were
included in the analyses relating to FII:C. Mean FII:C in
patients was 112.2% (5th–95th percentile 90.0–135.2%) and in
control subjects 110.6% (5th–95th percentile 89.0–134.0%), a
difference of 1.6% (95%CI: 0.8–2.4). Elevated FII:Cwas a risk
factor for thrombosis (Table 2). Adjustment for age and sex
did not affect the crude OR (data not shown). However,
adjustment for sex, age and BMI reduced the OR. Individuals
with FII:C in the uppermost quartile had only a slightly
increased risk of venous thrombosis compared to those with
Table 1 Effect of the FII19911-G allele on venous thrombotic risk
Genotype
Patients
n (%)
Controls
n (%)
Odds ratio
(95% CI)
FII19911
AA (%) 1039 (23.8) 1276 (26.7) 1*
AG (%) 2072 (47.5) 2336 (48.9) 1.09 (0.98–1.20)
GG (%) 1254 (28.7) 1167 (24.4) 1.32 (1.18–1.48)
FII19911(excluding FII20210-A carriers)
AA (%) 918 (22.2) 1224 (26.1) 1*
AG (%) 1972 (47.6) 2296 (49.0) 1.15 (1.03–1.27)
GG (%) 1253 (30.2) 1167 (24.9) 1.43 (1.27–1.61)
FII19911(excluding FII20210-A and factor V Leiden carriers)
AA (%) 770 (22.1) 1152 (26.0) 1*
AG (%) 1647 (47.2) 2174 (49.0) 1.13 (1.01–1.27)
GG (%) 1071 (30.7) 1113 (25.1) 1.44 (1.27–1.63)
*Reference category.
Table 2 Prothrombin activity and venous thrombotic risk (including only subjects with known body mass index)
Prothrombin
activity (%)
Patients
n ¼ 1943 (%)
Controls
n ¼ 2736 (%)
Odds ratio
(95% confidence interval)
Odds ratio*
(95% confidence interval)
£ 101 451 (23.2) 697 (25.5) 1 1
102–109 388 (20.0) 666 (24.3) 0.90 (0.76–1.07) 0.86 (0.72–1.02)
110–119 507 (26.1) 692 (25.3) 1.13 (0.96–1.34) 1.03 (0.87–1.22)
‡ 120 597 (30.7) 681 (24.9) 1.35 (1.15–1.59) 1.15 (0.97–1.36)
*Adjustment for sex, age and body mass index. Reference category.
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values in the lowest FII:C quartile (adjusted OR 1.15; 95%CI:
0.97–1.36). We found similar results when we analyzed only
subjects with DVT in the leg (no PE) who did not have a
malignancy (adjusted OR 1.17; 95% CI: 0.96–1.43). To assess
in more detail the thrombotic risk of elevated FII:C, we
stratified FII:C in the control subjects into deciles and
calculated the ORs of each decile compared to the lowest
decile (Fig. 1). TheORswere less than one for the second to the
sixth deciles and were above one for the seventh to the tenth
deciles. The highest OR was found for the tenth decile
(‡ 129%) compared to the first decile (£ 93%) (OR 1.31;
95%CI: 1.01–1.70). Adjustment for sex, age and BMI reduced
these ORs (graph not shown).
Among the control subjects, the mean FII:C in 19911-AA, -
AG and -GG was 107.4%, 110.7% and 113.6%, respectively.
The mean FII:C differences were 3.4% (95% CI: 2.1–4.6) for
19911-AG vs. -AA, and 6.2% (95% CI: 4.8–7.6) for -GG vs. -
AA. Among the control subjects with FII20210-GG, the mean
FII:C differences were 3.9% (95% CI: 2.7–5.1) for 19911-AG
vs. -AA, and 7.1% (95%CI: 5.7–8.5) for -GG vs. -AA. Table 3
shows that the FII20210A allele had a much stronger influence
on FII:C than the FII19911G allele. The FII19911G allele,
compared to the FII19911A allele, was associated with a higher
meanFII:C in FII20210-GG, but the difference is small and the
confidence interval wide. Among FII20210-GA control carri-
ers, the mean FII:C differences (95%CI) was 1.7% ()7.2–10.7)
for 19911-AG vs. -AA.
Venous thrombotic role of the FII19911G allele in 20210A
carriers and FV Leiden carriers
Table 4 shows that among FII20210-GA carriers the
FII19911G allele had only a slight affect on thrombotic risk
(OR 1.09; 95% CI: 0.67–1.79 for 19911-AG vs. -AA).
Adjustment for age and sex did not affect this OR. We found
a similar result when we analyzed only subjects with DVT in
the leg (no PE) without malignancy (OR 1.15; 95% CI: 0.67–
1.96). Excluding FV Leiden carriers hardly changed the risk
(OR 1.14; 95% CI: 0.69–1.90).
The FII19911G allele, compared to the FII19911A allele,
increased thrombotic risk amongFVLeiden carriers [OR (95%
CI) ¼ 1.21 (0.86–1.71) for 19911-AG vs. –AA, and 1.51 (1.00–
2.28) for -GG vs. -AA]. Adjustment for age and sex did not
affect these ORs. Excluding FII20210A carriers mildly
increased these adjusted ORs [OR (95% CI) ¼ 1.31 (0.92–
1.86) for 19911-AG vs. -AA, and 1.66 (1.09–2.51) for -GG vs. -
AA]. The SI for FVLeiden and FII19911-AGwas 1.12 and the
SI for FV Leiden and FII19911-GG was 1.15.
Discussion
Our study shows that individuals with FII19911-GG have a
1.3-fold increased risk of venous thrombosis compared to those
with FII19911-AA. This OR slightly increased after we
excluded FII20210A and FV Leiden carriers, indicating more
clearly its causal role on venous thrombotic risk. The FII19911-
AG genotype, compared with FII19911AA, slightly increased
the risk of venous thrombosis among both FII20210-GG
carriers and FII20210A carriers. The FII19911G allele com-
pared to the FII19911A allele increased the thrombotic risk in
FV Leiden carriers, with each additional G-allele increasing
risk by 20–30%.
Carriers of the FII19911G allele had a lower thrombotic risk
than carriers of FV Leiden and FII20210A. However,
FII19911G carriers had a similar population attributable risk
to FV Leiden and had a higher population attributable risk
than FII20210A. This is the result of a much higher prevalence
of FII19911G allele than FV Leiden and FII20210 in the
general population. The prevalence of the 19911A allele among
the control subjects (51.3%) was similar to previous reports
from a Dutch [11] (48.0%) and Spanish [12] (52.2 %)
population.
As previously reported [11,12], the 19911G allele was
associated with slightly elevated FII:C. Elevated FII:C is a
risk factor for venous thrombosis. However, in contrast with
earlier studies [3,21], after adjustment for age, sex and BMI, the
risk of thrombosis for elevated FII:C attenuated considerably
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Fig. 1. The venous thrombotic risk of elevated prothrombin activity. The
prothrombin levels of the control subjects were stratified into deciles.
Using the first decile as the reference group, crude odds ratios with 95%CI
were calculated for nine higher deciles. The prothrombin values of the first
to the tenth deciles are £ 93, 94–98, 99–102, 103–106, 107–109, 110–113,
114–117, 118–122, 123–128 and ‡ 129%.
Table 3 Prothrombin G20210A mutation, A19911G polymorphism and
plasma prothrombin activity in control subjects
FII20210 FII19911 n
Prothrombin activity (%)
Mean (95% CI) Range
GG AA 703 106.5 (105.5–107.4) 52–173
AG 1364 110.4 (109.7–111.0) 61–149
GG 701 113.6 (112.5–114.6) 50–152
Overall 2768 110.2 (109.7–110.7) 50–173
GA AA 26 131.7 (125.3–138.1) 104–165
AG 22 133.4 (126.9–140.0) 105–174
Overall 48 132.5 (128.1–136.9) 104–174
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[OR (95% CI) from 1.35 (1.15–1.59) to 1.15 (0.97–1.36) for the
highest FII:C quartile vs. the lowest FII:C quartile]. The lowest
risk of venous thrombosis was found for individuals with
prothrombin values between 94% and 109% (second to fifth
deciles) when using the lowest decile as a reference group. The
risk for those with values in the sixth decile (between 110% and
113%) was similar to those with the lowest levels (< 93%),
and increased for those with higher levels. This curve
approximates the J-curve that has been described as the
thrombin paradox [22], the relationship between thrombin
concentration and the thrombotic potential of blood. Throm-
bin acts both as an anticoagulant and as a procoagulant [23–
25]. Low thrombin levels generate markedly increased levels of
the endogenous circulating activated protein C (APC), leading
to an anticoagulant effect. In contrast, high thrombin levels
cause a procoagulant process by generating FVa and FVIIIa,
by converting fibrinogen to fibrin and by activating platelets
[22]. Thus, low levels (< 93%) may lack a protective
anticoagulant property and high prothrombin levels (higher
than 113%) are associated with a prothrombotic risk.
However, ignoring the lowest decile, the other nine deciles
show a dose–response relationship. Confirmation of these
results in other studies is warranted.
We found that the FII19911-AG genotype compared with
FII19911-AA only slightly increased the risk of venous
thrombosis in both carriers of the FII20210-GA genotype
(OR 1.09; 95%CI: 0.67–1.79) and carriers of the FII20210-GG
genotype (OR 1.15; 95% CI: 1.03–1.27). Excluding subjects
with PE or malignancy as conducted in the Leiden Thrombo-
philia Study (LETS) did not change this finding. Interestingly,
as in the LETS [11], we have shown that among FII20210-GA
carriers the mean FII:C was only slightly affected by the
FII19911 genotype. This probably explains why the FII19911-
AG genotype hardly affected the venous thrombotic risk
among FII20210-GA carriers. Our findings are based on a
much larger number of subjects than in earlier reports [11,12].
We found a high increased risk of venous thrombosis for
carriers of both FV Leiden and FII19911G alleles. Together
with previous reports [26,27] on the combined effect of FV
Leiden and FII20210A on the venous thrombotic risk, our
finding implies that prothrombin levels may modify venous
thrombotic risk in FV Leiden carriers. This may be partly
explained by an in vitro study [23] showing that prothrombin
could inhibit FVa inactivation by APC. Thus, increased
prothrombin levels may enhance the APC resistance of FV
Leiden [24]. Elevated prothrombin levels also cause a concen-
tration-dependent, thrombin activatable fibrinolysis inhibitor-
mediated inhibition of fibrinolysis [25].
This is the largest population-based case–control study on
venous thrombosis conducted so far. Although a proportion of
participants did not provide DNA (13.4% of patients, 22.8%
of control subjects), the sex and age distributions among
participants (either patients or control subjects) with and
without available DNA were similar. The unavailability of
DNA samples appeared to occur randomly and is unlikely to
depend on the status of the prothrombin gene. This excludes a
possible selection bias.
In conclusion, we have found that the FII19911G allele is a
risk factor for venous thrombosis, which is associated with
slightly elevated plasma prothrombin activity and slightly
increased thrombotic risk in FII20210-GG subjects. However,
among FII20210-GA carriers, prothrombin activity and
venous thrombotic risk were hardly affected by the
FIIA19911G genotype, in contrast to earlier studies. Further-
more, the FIIA19911G genotype appears to modify the
thrombotic risk in FV Leiden carriers.
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